Zanidatamab-hrii India Price & Patient Access Guide

 

Zanidatamab (Ziihera) 300 mg Injection available in India

A diagnosis of HER2-positive biliary tract cancer can present significant treatment challenges, particularly when the disease has progressed despite previous therapy. For eligible patients, advances in targeted cancer treatment have created new options that focus on specific molecular characteristics of the tumor rather than relying solely on conventional treatment approaches.

Zanidatamab-hrii is a HER2-directed bispecific antibody developed to target HER2-positive cancer cells through a dual-binding mechanism. Unlike therapies that interact with a single target site, Zanidatamab binds to two distinct extracellular domains of the HER2 receptor. This dual engagement promotes receptor internalization and reduces HER2 expression on the tumor cell surface.

In addition, Zanidatamab activates multiple immune-mediated pathways involved in cancer cell elimination, including complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP). Through these coordinated mechanisms, the therapy is designed to inhibit tumor growth and support the destruction of HER2-expressing cancer cells.

Who May Be Eligible for Zanidatamab?

Zanidatamab is indicated for adult patients with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC) identified through an FDA-approved diagnostic test.

Patients diagnosed with advanced biliary tract cancer often undergo multiple lines of treatment during the course of their disease. For individuals whose cancer demonstrates HER2 positivity and who have previously received treatment, Zanidatamab may represent a targeted therapeutic option that can be evaluated by the treating oncology team.

The therapy received accelerated approval based on findings related to overall response rate and duration of response. Continued approval for this indication remains dependent upon confirmation and verification of clinical benefit through ongoing studies.

Modern oncology increasingly focuses on identifying therapies that are directed toward specific molecular drivers of cancer. Zanidatamab was developed specifically to target HER2-positive tumors through a unique bispecific design.

By binding simultaneously to two HER2 binding sites, the therapy engages multiple biological processes involved in tumor control. This differentiated approach is intended to enhance HER2 targeting while activating immune-mediated mechanisms that contribute to cancer cell destruction.

For eligible patients with previously treated HER2-positive biliary tract cancer, this targeted approach provides an additional treatment option that may be considered as part of a comprehensive treatment strategy determined by the treating physician.

Administration and Recommended Dosage

Zanidatamab is administered as an intravenous infusion under medical supervision.

The recommended dosage is 20 mg/kg administered once every two weeks. Treatment is generally continued until disease progression or the development of unacceptable toxicity.

If a scheduled dose is delayed or missed, the dose should be administered as soon as possible, with future doses adjusted to maintain the recommended two-week dosing interval.

Recommended infusion durations include:

• First and second infusions: 120–150 minutes
• Third and fourth infusions: 90 minutes
• All subsequent infusions: 60 minutes, provided previous infusions were well tolerated

The medication should be administered through intravenous infusion using a 0.2 or 0.22 micron filter. Zanidatamab should not be administered as an intravenous push or bolus and should not be infused through the same intravenous line as other intravenous medications.

All dosing decisions, infusion schedules, and treatment monitoring should be carried out under the guidance of the treating healthcare team.

Potential Clinical Benefits

Patients and caregivers often seek a clearer understanding of the role a therapy may play within a treatment plan. Zanidatamab has been developed specifically for HER2-positive biliary tract cancer and provides a targeted treatment approach for eligible patients who have already received prior therapy.

The therapy combines dual HER2 targeting with activation of multiple immune-mediated mechanisms involved in tumor cell elimination. Through these actions, Zanidatamab is intended to inhibit tumor progression and contribute to anti-tumor activity in appropriately selected patients.

Treatment decisions should always be individualized based on disease characteristics, prior treatment history, biomarker status, and the recommendations of the treating oncology specialist.

Important Safety Information

As with all cancer therapies, careful monitoring is essential throughout treatment.

Zanidatamab has the potential to cause embryo-fetal toxicity. Pregnancy status should be verified in females of reproductive potential before treatment begins. Effective contraception is recommended during therapy and for four months following the final dose.

The safety and effectiveness of Zanidatamab have not been established in pediatric patients.

Clinical studies did not identify overall differences in safety or effectiveness between patients aged 65 years and older and younger adult patients.

Important risks and adverse reactions associated with Zanidatamab include:

• Embryo-fetal toxicity
• Left ventricular dysfunction
• Infusion-related reactions
• Diarrhea

Patients should promptly report any new or worsening symptoms to their healthcare provider and attend all recommended monitoring appointments throughout treatment.

Storage and Product Information

Zanidatamab is supplied as a sterile, preservative-free, white lyophilized powder for reconstitution.

Each single-dose vial contains 300 mg of Zanidatamab-hrii, and cartons contain two single-dose vials.

Storage requirements include:

• Refrigeration between 2°C and 8°C (36°F to 46°F)
• Storage in the original carton until reconstitution
• Protection from freezing

Maintaining appropriate storage conditions throughout handling and transportation is important to preserve product integrity.

Zanidatamab Availability in India

At present, Zanidatamab is not approved for routine commercial sale in India and is therefore unavailable through standard retail pharmacies or conventional pharmaceutical distribution channels.

Patients who have been prescribed Zanidatamab by their treating physician may still be able to access the medicine through regulated patient-specific import pathways. These pathways are intended to facilitate access to certain internationally available therapies when supported by valid medical documentation and regulatory approvals.

Because access requirements may vary depending on the individual case, patients and caregivers are encouraged to seek guidance regarding documentation, regulatory procedures, availability timelines, and procurement requirements before initiating the import process.

Price of Zanidatamab in India

The price of Zanidatamab in India is generally determined on a case-by-case basis following review of the required medical documents and prescription.

Several factors may influence the final cost, including:

• International supplier availability
• Country of origin
• Regulatory and documentation requirements
• Logistics and transportation costs
• Applicable taxes and duties
• Currency exchange fluctuations
• Manufacturer or supplier pricing updates

Patients seeking current pricing information may request a quotation after submission and verification of the required documentation.

Importing Zanidatamab into India

Accessing Zanidatamab through legal and compliant channels involves a structured import process designed to meet applicable regulatory requirements.

Step 1: Medicine Request Submission

The process begins when the patient or caregiver submits a request along with a valid prescription and relevant treatment information provided by the treating physician.

Step 2: Form 12A Submission

A completed Form 12A and a valid prescription issued by a Registered Medical Practitioner (RMP) are required to initiate the application process.

Step 3: Document Review

All submitted documents are reviewed to confirm compliance with regulations governing personal-use medicine imports in India.

Step 4: Regulatory Authorization

Following approval from the Drugs Controller General of India (DCGI), the import process proceeds according to the approved application.

Step 5: International Procurement

The medicine is sourced from licensed and authorized international suppliers to help ensure authenticity, quality standards and supply-chain integrity.

Step 6: Delivery Coordination

Once procurement and dispatch have been completed, logistics are arranged to facilitate delivery to the patient's designated location in India.

Documents Commonly Required

To process a Zanidatamab import request, the following documents are generally required:

• Valid prescription specifying medicine name, dosage, diagnosis and treatment duration.
• Recent medical records or diagnostic reports supporting the prescribed treatment.
• Government-issued photo identification.
• Residential address proof.
• Import permit, where applicable.

Requests are processed only after successful verification of all required documents.

Patient Support Throughout the Access Process

Obtaining a specialized oncology medicine from international sources can often appear complex for patients and caregivers. Support throughout the process can help simplify documentation requirements, regulatory procedures, procurement coordination and delivery planning.

Following regulatory approval, Zanidatamab is sourced through authorized international supply channels. Each order undergoes verification before dispatch, and procurement activities are conducted in accordance with applicable regulatory and quality standards.

Patients and caregivers may seek assistance regarding documentation requirements, prescription review, availability updates, pricing information, import timelines and delivery coordination.

Through established patient-specific import pathways, eligible patients in India may access Zanidatamab in a structured, transparent and compliant manner when prescribed by their treating healthcare professional.